Dr. Michaël Hocquemiller is in charge of the non-clinical development of Lysogene’s gene therapy products including preclinical studies and bioanalytical assays. Since 2010, Dr. Hocquemiller has co-led the Phase 1 clinical trial in MPS IIIA, as well as designing drug candidates and pre-clinical work that have now advanced into clinical development. Before joining Lysogene, Dr. Hocquemiller worked as a research scientist at the Pasteur Institute focused on neurophysiopathology and gene therapy of Lysosomal Storage Diseases.

Dr. Hocquemiller obtained his PhD in Neurosciences from the University Paris Descartes (Paris V), a Master’s in genetics from University Pierre and Marie Curie (Paris VI) and a Clinical Research Associate certification.